Clinical Dialogues: Lipids & Diabetes- UK- 2017
Stratford upon AvonDec. 6, 2017 - Stratford upon Avon
We are pleased to announce and invite you to attend the new Clinical Dialogues: Lipids & Diabetes The ‘Clinical Dialogues’ programme will expand on the tradition of the successful ‘Update’ series in Lipids, Diabetes and Hypertension initiated in 1993 in Cambridge.
The programme will continue the aims of these programmes to provide state-of-the-art education and help clinicians translate insights from recent scientific developments in cardiovascular medicine and diabetes to relevance for their daily clinical practice.
The programme is a two-day, CPD accredited educational meeting designed for full-time practising UK doctors with an interest in cardiovascular disease, lipids and diabetes.
The programme committee and scientific coordinators are:
- Prof. Neil Poulter - Imperial College London
- Prof. John Betteridge - University College London, Royal Society of Medicine
- Prof. Kausik Ray - Imperial College London
- Prof. Peter Sever - Imperial College London
- Prof. Simon Thom - Imperial College London
Agenda outline and programme topics
The new ‘Clinical Dialogues’ are initiated by renowned British experts in cardiovascular medicine and diabetes, who are committed to develop a state-of-the-art educational agenda that address the key issues that clinicians face in their daily practice managing lipids and T2DM. The agenda of the 2017 meeting includes a comprehensive review of the management of diabetes and lipid disorders and their management, as well as sessions covering current and emerging issues and developments. The programme consist of plenary lectures, debates and discussion ensuring lively interaction.
Day 1, December 6, 2017
Session 1 - Diabetes & Lipids
11.00 - 13.00
- Cardiovascular risk, the role of dysglycaemia and lipids
- Lipids & lipoproteins, what you need to know
- Is metabolic syndrome a useful concept?
- Glucose, lipids & the biology of atherosclerosis
- Origins of CVD, genes vs. environment
Session 2 - Diabetes Background
14.00 - 15.40
- Diagnosing type-2 diabetes
- Current guidelines for glucose management
- Why is metformin first line therapy?
- New hypoglycaemic agents & optimal combinations
- Insulin: how & for whom?
Session 3 - Treatments
16.10 - 17.50
- Current guidelines for lipid management
- Familial hypercholesterolemia principles of diagnosis & management
- Other familial lipid disorders
- Monoclonal antibodies to PCSK9, latest news & implications for guidelines
- Profiles of other new lipid lowering therapies: advantages & disadvantages
Day 2, December 7, 2017
Session 4 - Lifestyle & prevention
08.30 - 09.30
- Diet & lifestyle for type-2 diabetes prevention & management
- Can diet cure type-2 diabetes?
- Exercise for CVD prevention
Session 5 - Risks
09.30 - 10.30
- Hypoglycaemia & cardiovascular outcomes
- Blood pressure & lipid lowering management in type-2 diabetes
- Heart failure in type 2 diabetes
Session 6 - Targets
11.00 - 12.20
- Is residual risk a real therapeutic challenge?
- Lipid targets beyond LDL, HDL & Lp(a)
- The statin intolerant patient: myth or reality
- Statin intolerance: what to do in the clinic
Session 7 - Difficult problems
12.20 - 13.20
- Surgical treatment of type-2 diabetes
- Maturity onset diabetes of the young
- Erectile dysfunction in hypertension & diabetes
Sesion 8 - Complexities
14.20 - 15.40
- Which hypoglycaemic drugs lower cardiovascular risk?
- Explaining the trial results for empagliflozin, liraglutide & semaglutide
- Where are we with triglycerides?
- The re-emergence of pioglitazone
Session 9 - Debate
16.10 - 17.10
- The impact of renal impairment on CVD risk in type-2 diabetes
- Debate: Proteinuria – fool’s gold?
- Lipid lowering over the last 50 years a personal view
Who should participate?
The meeting is aimed at mainly hospital physicians with an interest in cardiovascular disease, lipids and diabetes.
CPD accreditation will be applied for from the Royal College of Physicians of London
The registration will open soon